Skip to main content
Premium Trial:

Request an Annual Quote

McKinley, New Objective Partner on LC-MS Applications

NEW YORK (GenomeWeb News) – McKinley Scientific and New Objective today announced a co-marketing and development deal for the expansion of applications for liquid chromatography-mass spectrometry systems.

Sparta, NJ-based McKinley will provide financing and support services for mass spectrometry, while Woburn, Mass.-based New Objective is providing its nanospray front end technologies. Together, the firms will co-market their products and develop distribution and services to deliver mass spec solutions, they said.

Further financial and other details were not disclosed.

"Our combined customer focus will yield broader and more powerful solutions with expanded choices, adaptability, and education opportunities," McKinley President and CEO Paul Corcoran said in a statement.

McKinley Scientific is an asset management company that helps clients with planned approaches and access to instruments, according to its website.

New Objective Co-founder and President Gary Valaskovic said, "The combination of New Objective¹s world class front-end hardware and consumables, with the outstanding finance, sales, and support structure of McKinley Scientific is a winning combination for the customer, one that will enable the development of new markets for both organizations."

New Objective provides consumables and hardware for mass spec-based proteomics research.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.